For translational oncology, the useful question is not “Which analyte is better?” It is “Which biological question requires which analyte?” ctDNA has greater clinical and regulatory maturity for several molecular applications. CTCs preserve intact cells that can support phenotypic and functional research that fragmented DNA cannot.
What ctDNA does especially well
ctDNA is tumor-derived DNA released into the circulation. It can support sensitive, serial measurement of genomic and epigenomic features without requiring recovery of intact tumor cells. Contemporary reviews describe applications including detection of somatic variants, copy-number changes, methylation patterns and molecular monitoring.
What an intact viable CTC can preserve
A circulating tumor cell is a whole cell. That means it can retain morphology, protein expression, cellular organization and—when recovered viable—the possibility of downstream cell-based experimentation. Reviews of viable CTC research describe culture, molecular profiling and functional studies, while also emphasizing that CTC rarity and recovery remain significant technical constraints.
| Question | ctDNA | Viable CTCs |
|---|---|---|
| Somatic mutation / molecular fragment analysis | Strong fit | Possible after cell recovery, but usually less direct |
| Serial blood sampling | Strong fit | Possible, subject to recovery/yield |
| Whole-cell phenotype | Not preserved | Potentially available |
| Live-cell perturbation | Not possible on DNA fragments | Potentially possible if viability is preserved |
| Cell-level trajectory over time | Not a same-cell measurement | Potentially possible with identity-preserved workflows |
The commercial implication for VitraCell
VitraCell positions viable-cell analysis as an orthogonal layer to ctDNA. When a translational question requires an intact living cell—particularly a question about phenotype, perturbation response or cell history before a terminal molecular endpoint—viable-cell measurement can address information that DNA fragments do not preserve.
Recovering a viable tumor-associated cell is only useful if the downstream state-to-fate record changes a research decision. That incremental value remains to be demonstrated experimentally.
What still has to be proven
Published CTC biology does not validate VitraCell, Vimeran or Delta State Response. VitraCell still has to establish recovery, viability, identity retention, repeatable measurement and incremental information beyond appropriate baseline and endpoint comparators.
Selected sources
- Circulating tumor cells and tumor-derived cell-free DNA in cancer management: clinical evidence, limitations, and future directions (2026).
- Smit & Pantel. Circulating tumor cells as liquid biopsy markers in cancer patients (2024).
- Pantel & Alix-Panabières. Functional Studies on Viable Circulating Tumor Cells (2016).
- Circulating Tumor Cells: Isolation, Preclinical Models, and Clinical Applications for Personalized Cancer Therapy (2026).